Paul Rennie, recently presented at the Hong Kong Ignite Investment Summit, outlining the company’s late-stage osteoarthritis program and upcoming catalysts. The presentation focused on the global Phase 3 PARA_OA_012 trial, including strong recruitment momentum, the significance of the interim analysis expected in 2026, and the broader commercial opportunity for injectable PPS (Zilosul®) in a large, underserved OA market. Paul also highlights Paradigm’s regulatory positioning, global site expansion, and strategy to unlock a value inflection post-interim analysis.